Ventyx Biosciences Acquired by Eli Lilly — Healthcare M&A

Eli Lilly has entered into a definitive agreement to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion. The strategic merger expands Lilly’s healthcare and pharmacy pipeline with a focus on developing oral therapies for inflammatory-mediated diseases. The deal is positioned as a way to add differentiated small-molecule programs targeting immune pathways implicated in chronic inflammation.

Ventyx is developing oral small-molecule candidates, including NLRP3 inhibitors, designed to address inflammation across multiple therapeutic areas such as cardiometabolic conditions, neurodegenerative disorders, and autoimmune and inflammatory diseases. The acquisition reflects broader industry interest in inflammation as a driver of chronic disease and a continued emphasis on oral treatment options that can potentially improve patient access and long-term management.

The transaction is expected to close in the first half of 2026, subject to regulatory approvals and Ventyx stockholder consent. Once completed, Ventyx’s clinical-stage pipeline is expected to be integrated into Lilly’s inflammation-focused R&D efforts, reinforcing the buyer’s strategy to build out its portfolio in immune-mediated disease areas.